AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05159739 — intervention group
Intervention type: GENETIC
Intervention: Blood Draw or Saliva/Cheek Cell Sample:
Description: Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
Study NCT04850365 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysteropexy
Description: Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion.
Study NCT03906474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage controlled human P. falciparum malaria infection
Description: Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.
Study NCT02240680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching linagliptin 5 mg
Study NCT02240680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: 5 mg once a day
Study NCT05299710 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
Study NCT01694875 — intervention group
Intervention type: DEVICE
Intervention: APTIMA HPV Assay
Description: In Vitro Diagnostics Assay
Study NCT05275270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin gel
Description: The active oxytocin gel (A) consisted of oxytocin dissolved in a gel-based on hypromellose with a pH of 3.8. 1 ml of gel contained 600 IU of oxytocin
Study NCT02985125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
Study NCT02985125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
Study NCT04207112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
Study NCT04207112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
Study NCT04207112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
Study NCT04207112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
Study NCT04207112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
Study NCT04207112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Drugs
Description: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
Study NCT01891747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab at 10mg/kg IV every 14 days (Phase I \& phase II)
Study NCT01891747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2/day for a 5-day regimen per month (Phase I \& Phase II)
Study NCT01891747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 250 mg vitamin C once a day (oral) - Phase I \& Phase II
Study NCT04676139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 10 mg capsules once daily for 12 months
Study NCT04676139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for 12 months
Study NCT03935477 — intervention group
Intervention type: DEVICE
Intervention: WellBeing catheter
Description: Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
Study NCT02407574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Pacing Box
Description: Atrial pacing using an external pacing box
Study NCT01888354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel (repository corticotropin injection)
Description: Acthar Gel 80 IU
Study NCT00554294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: environmental and behavioral change
Description: In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
Study NCT01581112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microbial transplant
Description: Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
Study NCT00614003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision support skills building Intervention
Description: Decision support skills
Study NCT03907722 — intervention group
Intervention type: OTHER
Intervention: Long pentraxin 3
Description: Primary PCI
Study NCT02619240 — intervention group
Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: performance of bronchoscopy with BAL
Study NCT02089386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Study NCT02089386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Study NCT03777956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
Study NCT03777956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo are given as capsules and taken orally twice a day.
Study NCT03067766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Participate in a comic art creation workshop
Study NCT03067766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo qualitative interviews
Study NCT03067766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03067766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00907140 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron Emission Tomography
Description: FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
Study NCT03345836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Upadacitinib
Description: Matching placebo tablets
Study NCT03345836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablets
Study NCT01511289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: 400mg/Tab, QD
Study NCT01511289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: 100mg or 200mg/Capsule, 300mg or 400mg BID
Study NCT03502759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHICA SUDEP module
Description: CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
Study NCT02458612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
Study NCT05275270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: The placebo gel (B) consisted of the gel alone
Study NCT02458612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intervention group
Description: Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly.
Study NCT02815397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: given in addition to standard of care treatment
Study NCT02696785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC
Study NCT02696785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC
Study NCT02696785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT02696785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02696785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study NCT01146808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil and hepatitis B vaccination
Description: Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
Study NCT05108727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser
Description: DL with a wavelength of 810±5 nm, a 400micron diameter, and a power of 1 watt in continuous mode was applied to the MWF at the test sites.
Study NCT05108727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Widman Flap
Description: Periodontal Surgery Technique
Study NCT04436510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily
Study NCT04436510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdiperstat
Description: Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily
Study NCT05108727 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Modified Widman Flap
Description: Periodontal Surgery Technique
Study NCT00813007 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 5 Questionnaires at differing times before and after surgery.
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 3 mg administered SC
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 6 mg administered SC
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 12 mg administered SC
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 24 mg administered SC
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 0.1 mg/kg administered IV
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 0.2 mg/kg administered IV
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 0.4 mg/kg administered IV
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 0.8 mg/kg administered IV
Study NCT04183192 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (administered either IV or SC)
Study NCT03888703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional ablative CO2 laser
Description: Three treatments with a fractional ablative CO2 laser 8 weeks apart
Study NCT00691197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose sodium and Glycerin
Description: Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
Study NCT00691197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose sodium
Description: Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
Study NCT01344811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
Study NCT01925170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging
Description: Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
Study NCT01925170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Mammography
Description: Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
Study NCT01925170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium (99mTc) sestamibi
Description: Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
Study NCT04751513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Pressure on auricular point of Shenmen (TF4), Sympathesis (AH6a), Subcortex (AT4), Endocrine (CO18), finger (SF1), and toe (AH2) of the ear.
Study NCT03637595 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 3 sessions of acupuncture will be the reference therapy against which the energy medicine intervention is being compared.
Study NCT03637595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enery Medicine Intervention
Description: 3 sessions performed by Energy Medicine practitioner, who will perform an assessment followed by the intervention.
Study NCT03637595 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Energy Medicine
Description: a non-energy trained confederate to be determined from the clinical research coordinators and non traditional volunteers enrolled administering assessments and providing therapeutic company.
Study NCT01603121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisofylline
Description: Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
Study NCT03574701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
Study NCT01344811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
Study NCT01823822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral protein supplement (Tested product)
Description: Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
Study NCT03862482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)
Description: Brånemark® implant placed at sites 2 (left medial) and 5 (right distal), Swede-Vent® implant placed at sites 1 (left distal) and 4 (right medial), Screw-Vent® implant placed at site 3 (para symphysis)
Study NCT03862482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)
Description: Brånemark® implant placed at site 3 (para symphysis), Swede-Vent® implant placed at sites 2 (left medial) and 5 (right distal), Screw-Vent® implant placed at sites 1 (left distal) and 4 (right medial)
Study NCT03862482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)
Description: Brånemark® implant placed at sites 1 (left distal) and 4 (right medial), Swede-Vent® implant placed at site 3 (para symphysis), Screw-Vent® implant placed at sites 2 (left medial) and 5 (right distal)
Study NCT02682017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pork meat from pigs feed with a standard feed.
Description: 4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
Study NCT02682017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pork meat from pigs fed a feed with a Laminarin/fucoidan mix
Description: 4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
Study NCT01823822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iso-caloric supplement (Control product)
Description: Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
Study NCT03077945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback and cognitive reappraisal
Study NCT03077945 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control tasks
Study NCT01678807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-8237 6 DU
Study NCT02705716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride (1100ppm fluoride)
Description: Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
Study NCT02705716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.76% sodium monofluorophosphate (1000ppm fluoride)
Description: Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
Study NCT01678807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-8237 12 DU
Study NCT01678807 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03304483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 246-km running
Description: Spartathlon 2017
Study NCT01636869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block.